Panorama test for 22q11.2 (DiGeorge syndrome)
The Panorama non-invasive prenatal test on the mother’s blood, from 9 completed weeks of pregnancy. In addition to trisomies 21, 18 and 13, sex chromosome conditions and triploidy, it assesses the risk of the 22q11.2 microdeletion (DiGeorge syndrome), the most common microdeletion linked to birth defects and developmental delay.
Preparation and sampling
- Preparation
- Guide to preparing for tests
- Sample
- Blood
- Results available in
- 14 working days
- Where it is done
- All laboratories and map
Description
About the test
Panorama is a non-invasive prenatal test (NIPT): it analyses the cell-free DNA in a sample of the mother’s blood, part of which comes from the placenta, that is, from the baby. It carries no risk of miscarriage, because it is done on an ordinary venous blood sample. In addition to the most common chromosome number conditions, this version of the test also assesses the risk of the 22q11.2 deletion.
From the cell-free DNA, the test estimates the number of copies of the chromosomes and chromosome regions examined. Panorama uses SNP-based technology (single nucleotide polymorphisms, small differences in DNA that are unique to each person), which allows it to tell the mother’s DNA apart from the baby’s; this also allows it to detect triploidy and to determine zygosity in twins. The test’s performance for the 22q11.2 deletion was evaluated in the SMART study, the largest multicentre study of SNP-based non-invasive prenatal testing.
The test assesses the risk of the following conditions in the baby:
- Trisomy 21 (Down’s syndrome) – the most common chromosomal condition in newborns; it involves learning disability of varying degree, characteristic facial features and frequent heart defects.
- Trisomy 18 (Edwards’ syndrome) – a severe condition with growth restriction, heart and kidney defects and severe learning disability; life expectancy is very limited.
- Trisomy 13 (Patau’s syndrome) – severe malformations of the brain, heart and kidneys and cleft lip and palate; most affected babies do not survive their first year.
- Turner syndrome (45,X) – in girls; short stature, underdeveloped ovaries and infertility, sometimes heart defects; intelligence is usually normal.
- Klinefelter syndrome (47,XXY) – in boys; taller stature, small testes and infertility, sometimes learning difficulties.
- Jacobs syndrome (47,XYY) – in boys; often without obvious signs, sometimes taller stature and learning or behavioural difficulties.
- Triple X syndrome (47,XXX) – in girls; usually without symptoms, sometimes learning and speech difficulties.
- Triploidy – a whole extra set of chromosomes (69 instead of 46); the baby is as a rule not able to survive, and such a pregnancy can also cause complications for the mother, so early detection matters.
- 22q11.2 microdeletion (DiGeorge syndrome) – a small missing part of chromosome 22; it is linked to congenital heart defects, low calcium in the newborn, weakened immunity, developmental delay and characteristic facial features.
The test can also determine the baby’s sex. In twin pregnancies it assesses the risk of trisomies 21, 18 and 13 and can determine whether the twins are identical or non-identical and the sex of each baby, while the scope of the other assessments depends on the type of twin pregnancy. Knowing the zygosity matters: identical twins may share one placenta, which carries a risk of complications such as twin-to-twin transfusion syndrome, so such pregnancies need closer monitoring by a fetal medicine specialist.
When it is recommended
Trisomies 21, 18 and 13 and sex chromosome conditions are the most common chromosomal conditions screened for in pregnancy, and the 22q11.2 deletion is the most common microdeletion linked to birth defects and developmental delay. Unlike the trisomies, its risk does not rise with the mother’s age. Knowing early that the risk is raised allows timely genetic counselling, targeted examinations (for example a scan of the baby’s heart) and planning of further pregnancy care and the birth. The test is recommended:
- for pregnant women who want an extended, non-invasive assessment of the baby’s genetic risk;
- for women with an ultrasound finding that needs further assessment (for example a suspected heart defect) or with birth defects in the family;
- for pregnant women over 35, in whom the risk of trisomies is higher, but also for younger women, because the 22q11.2 deletion is not related to the mother’s age;
- in natural pregnancies and pregnancies after IVF;
- for women who want early detection of DiGeorge syndrome without invasive procedures.
In twin pregnancies, pregnancies with a donor egg and surrogate pregnancies the scope of the test is narrower, and the test is not recommended for pregnancies with more than two babies.
Preparation
- The test is done from 9 completed weeks of pregnancy; the length of the pregnancy should be confirmed by ultrasound.
- You do not need to fast, and the sample can be given at any time of day.
- At sampling, a form with details of the pregnancy is completed (length of pregnancy, number of babies, IVF, donor egg or surrogate pregnancy). Bring your ultrasound report and your doctor’s referral, if you have one.
- If you have had a blood transfusion or an organ or bone marrow transplant, say so before sampling.
- Before the test, it is advisable to discuss with your gynaecologist or a geneticist what the test can and cannot detect.
Sample
Venous blood from the mother. Cell-free DNA is extracted from the plasma and then analysed in a specialised laboratory.
Interpreting the results
- Low risk – it is very unlikely that the baby has any of the conditions examined. However, the test does not detect all chromosomal conditions, all microdeletions, single-gene disorders or structural defects, so regular ultrasound scans, including the anomaly scans in the first and second trimesters, remain essential.
- High risk – the test is a screening test, not a diagnosis. The result should be confirmed by an invasive diagnostic procedure (chorionic villus sampling or amniocentesis) and genetic analysis of the sample: a karyotype and, for the 22q11.2 deletion, FISH or chromosomal microarray (arrayCGH), because microdeletions are not visible on a standard karyotype. A discussion with a geneticist and a gynaecologist is essential, and decisions about the pregnancy are not made on the basis of this test alone.
- No result – sometimes no result can be issued; a repeat sample may then be needed.
Your doctor interprets the result together with your symptoms and other findings.
What can affect the result
- too low a proportion of the baby’s DNA in the mother’s blood (the fetal fraction), for example early in pregnancy, which sometimes means no result can be issued;
- an incorrectly estimated length of pregnancy, which is why it should be confirmed by ultrasound;
- a blood transfusion or an organ or bone marrow transplant, as another person’s DNA can affect the result;
- the placental origin of the baby’s cell-free DNA: the chromosomes of the placenta occasionally differ from those of the baby, which can lead to a false-positive or false-negative result;
- the type of pregnancy: with twins, a donor egg or a surrogate pregnancy the scope of the test is narrower, and with more than two babies the test is not done.
Related tests
- fetal anomaly ultrasound scans in the first and second trimesters and, if needed, a scan of the baby’s heart;
- Panorama with microdeletions, to assess four further microdeletion syndromes;
- chorionic villus sampling or amniocentesis with FISH or chromosomal microarray (arrayCGH) to confirm a raised risk;
- genetic counselling before and after the test.
Frequently ordered together
How to order tests online?
Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.
Payment method:
- Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
- At the laboratory – order your tests online and pay for them when you come to the laboratory.
After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.